Cargando…

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer

Detalles Bibliográficos
Autor principal:	Tripathy, Sambit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388337/ https://www.ncbi.nlm.nih.gov/pubmed/34465966 http://dx.doi.org/10.4103/iju.IJU_542_20

Ejemplares similares

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
por: Uemura, Hiroji, et al.
Publicado: (2020)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2021)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

PROMPTS Trial: Screening spinal magnetic resonance imaging in castration-resistant prostate cancer
por: Pattnaik, Soumya Shivasis
Publicado: (2023)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
por: Shore, Neal, et al.
Publicado: (2019)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2021)

Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
por: Chowdhury, Simon, et al.
Publicado: (2021)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2023)

Which one is better, Wallace or Bricker?
por: Khurana, Naval, et al.
Publicado: (2007)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Urethral reconstructive surgery: Which catheters are better?
por: Suryavanshi, Manav, et al.
Publicado: (2008)

Miniaturized percutaneous nephrolithotomy: Is smaller really better?
por: Sharma, Gopal
Publicado: (2021)

Is there a better indicator for predicting the outcome of trial without catheter?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
por: Chowdhury, Simon, et al.
Publicado: (2019)

Defining the role of antioxidants in the prevention of prostate cancer
por: Pathak, Hemant R., et al.
Publicado: (2009)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

The current role of Active Surveillance in early prostate cancer
por: Shrinivas, R. P., et al.
Publicado: (2009)

Safety and efficacy of active surveillance in patients with localized prostate cancer
por: Mavuduru, Ravimohan, et al.
Publicado: (2008)

Prostate cancer treatment does not increase the risk of cardiovascular events
por: Khochikar, Makarand V.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_kivqvc39i1s45vh0j7f3qee1i0